| |  Online-Ressource |
|---|
| Verfasst von: | Domingo-Domènech, Eva [VerfasserIn]  |
|---|
| | Boumendil, A. [VerfasserIn] |
|---|
| | Climent, F. [VerfasserIn] |
|---|
| | Sengeloev, H. [VerfasserIn] |
|---|
| | Wahlin, B. [VerfasserIn] |
|---|
| | Wattad, W. [VerfasserIn] |
|---|
| | Arat, M. [VerfasserIn] |
|---|
| | Finel, H. [VerfasserIn] |
|---|
| | Schapp, N. [VerfasserIn] |
|---|
| | Ganser, A. [VerfasserIn] |
|---|
| | Yeshurun, M. [VerfasserIn] |
|---|
| | Pavone, V. [VerfasserIn] |
|---|
| | Snowden, J. [VerfasserIn] |
|---|
| | Finke, J. [VerfasserIn] |
|---|
| | Montoto, S. [VerfasserIn] |
|---|
| | Sureda, A. [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| Titel: | Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma |
|---|
| Titelzusatz: | a retrospective analysis of the lymphoma working party (LWP) of the EBMT |
|---|
| Verf.angabe: | E. Domingo-Domènech, A. Boumendil, F. Climent, H. Sengeloev, B. Wahlin, W. Wattad, M. Arat, H. Finel, N. Schapp, A. Ganser, M. Yeshurun, V. Pavone, J. Snowden, J. Finke, S. Montoto, A. Sureda, P. Dreger |
|---|
| Jahr: | 2020 |
|---|
| Jahr des Originals: | 2019 |
|---|
| Umfang: | 8 S. |
|---|
| Fussnoten: | Published online: 6 November 2019 ; Gesehen am 21.04.2020 |
|---|
| Titel Quelle: | Enthalten in: Bone marrow transplantation |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 55(2020), 4, Seite 796-803 |
|---|
| ISSN Quelle: | 1476-5365 |
|---|
| Abstract: | Systemic anaplastic large cell lymphoma (sALCL) is a rare histological entity expressing the CD30 antigen that comprises around 11% of peripheral T-cell lymphoma. We analysed the outcome of patients with relapsed/refractory sALCL treated with autologous stem cell transplantation (auto-HCT). We included 65 adult patients (42 males; median age, 44 years); 24 patients had an ALK-ve sALCL. Fifty-one patients had chemosensitive disease at the time of transplant. Ten patients (15%) were treated with brentuximab vedotin (BV) before auto-HCT (median number of doses: 5). The median follow-up for surviving patients was 35 months (3-71). Three-year cumulative incidence of nonrelapse mortality and of relapse were 1.7% and 34%, respectively. Three-year progression-free survival and overall survival were 64% and 73%, respectively. No prognostic factors for any of the outcomes analysed were found in univariate analysis. There were no significant differences in any of the outcomes between patients who had received BV and the remainder. This is the largest analysis presented so far analysing the role of auto-HCT in patients with relapsed/refractory sALCL, showing a promising PFS and OS in this high-risk population. The potential impact of the administration of BV as salvage strategy before the procedure needs to be further elucidated. |
|---|
| DOI: | doi:10.1038/s41409-019-0734-7 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/s41409-019-0734-7 |
|---|
| | Volltext: https://www.nature.com/articles/s41409-019-0734-7 |
|---|
| | DOI: https://doi.org/10.1038/s41409-019-0734-7 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 169526925X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma / Domingo-Domènech, Eva [VerfasserIn]; 2020 (Online-Ressource)
